What is Elekta?
Headquartered in Stockholm, Sweden, Elekta operates at the intersection of advanced engineering and clinical oncology. The company specializes in the development, manufacturing, and distribution of sophisticated radiation therapy and radiosurgery systems. Its comprehensive portfolio includes industry-standard linear accelerators, the renowned Gamma Knife systems, and integrated oncology information software. By providing end-to-end clinical management solutions, Elekta enables healthcare providers to deliver highly precise treatments for cancer and complex brain disorders, maintaining a dominant position in the global medical device landscape.
How much funding has Elekta raised?
Elekta has raised a total of $200M across 1 funding round:
Debt
$200M
Debt (2011): $200M, investors not publicly disclosed
Key Investors in Elekta
Undisclosed Institutional Partner
A major institutional entity providing debt financing to support large-scale enterprise operations and capital expenditure requirements.
Strategic Debt Syndicate
A consortium of financial institutions specializing in structured debt instruments for established medical technology corporations.
Global Capital Markets Group
An investment group focused on providing liquidity to multinational firms within the healthcare and life sciences sectors.
What's next for Elekta?
With a robust foundation established by its recent capital allocation, Elekta is positioned to accelerate its digital transformation and expand its footprint in emerging markets. The strategic focus will likely shift toward enhancing its software-as-a-service (SaaS) oncology platforms and integrating artificial intelligence into treatment planning workflows. As the demand for non-invasive, precision-based cancer care continues to rise, Elekta is well-equipped to leverage its technological infrastructure to drive long-term value for stakeholders and improve patient outcomes on a global scale.
See full Elekta company page
